Splunk Smashes Estimates and Makes a Big Acquisition
As its cloud-based subscription model gains steam, Splunk's latest purchase significantly expands its repertoire.
Simon Property Group Wants to Be More Than Just a Mall Operator
With retailers struggling, the REIT is diversifying its real estate business.
Growth Slowed at TJX Last Quarter, but It's No Big Deal
The leading off-price retailer saw a slowdown in comp sales growth last quarter, but it remains on track for strong long-term growth in sales and earnings.
Find out how earnings and other factors hit these stocks.
The company owns Priceline and a number of other travel websites.
These stocks managed to climb even on a mixed day for the broader market.
Virtual banks are looking to disrupt Hong Kong's banking sector. But how much of a threat are they to the traditional banks and their businesses?
After the company's miserable performance so far in 2019, investors are beginning to see glimmers of hope that the worst is behind it.
Let's look at whether the Latin American carrier's shares deserve the premium they're currently enjoying in the airline industry.
More of the same cash-flow concerns surfaced on strong momentum for its cloud-based subscription model.
After a quarterly report that wasn't as terrible as expected, shares of the high-end retailer were climbing.
Keysight delivered a beat-and-raise quarter after Huawei headwinds weren't as bad as expected.
The top dog in online retail and a fast-growing e-commerce specialist are market darlings, but only one will have the bigger gains in the year ahead.
Roughly half of Americans don't have any money in the stock market -- if you're in that group, here's how you can get started now!
The Norwegian software maker posted solid second-quarter results.
This Chinese e-commerce services provider still has plenty of room to run.
A 20% share-price slide may offer an opportunity to get in ahead of earnings.
Here's what to expect from the 2019 iPhones.
Zoom's valuation corresponds to high expectations.
The search giant casts off desserts.
Weak guidance wasn't enough to derail the stock.
HSBC's shares have fallen over 10% since late July. But does this Asian banking giant still have long-term potential?
Retrophin's PKAN drug candidate missed the mark in a late-stage trial.